Equities research analysts expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) to announce earnings per share of ($0.86) for the current quarter, Zacks reports. Two analysts have made estimates for Clarus Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($1.13). The business is expected to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Clarus Therapeutics will report full year earnings of ($2.47) per share for the current fiscal year, with EPS estimates ranging from ($3.38) to ($1.98). For the next financial year, analysts forecast that the business will report earnings of ($1.19) per share, with EPS estimates ranging from ($1.32) to ($1.06). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Clarus Therapeutics.
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) last posted its quarterly earnings data on Wednesday, March 30th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.49.
NASDAQ:CRXT traded down $0.51 on Friday, reaching $1.80. The stock had a trading volume of 14,765,596 shares, compared to its average volume of 23,435,608. Clarus Therapeutics has a 12-month low of $0.61 and a 12-month high of $31.24. The company has a 50-day moving average of $1.14 and a 200 day moving average of $2.62.
Institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new position in shares of Clarus Therapeutics during the 4th quarter valued at $31,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Clarus Therapeutics during the 4th quarter valued at $51,000. Cowen AND Company LLC bought a new position in shares of Clarus Therapeutics during the 3rd quarter valued at $53,000. Powell Investment Advisors LLC raised its holdings in shares of Clarus Therapeutics by 48.8% during the 4th quarter. Powell Investment Advisors LLC now owns 64,000 shares of the company’s stock valued at $156,000 after purchasing an additional 21,000 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Clarus Therapeutics during the 3rd quarter valued at $160,000. Institutional investors and hedge funds own 78.61% of the company’s stock.
Clarus Therapeutics Company Profile (Get Rating)
Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.
- Get a free copy of the StockNews.com research report on Clarus Therapeutics (CRXT)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.